<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=iso-8859-2"><meta name=Generator content="Microsoft Word 15 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Garamond;
panose-1:2 2 4 4 3 3 1 1 8 3;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin-top:0cm;
margin-right:0cm;
margin-bottom:8.0pt;
margin-left:0cm;
line-height:105%;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.E-potniSlog18
{mso-style-type:personal;
font-family:"Garamond",serif;
color:windowtext;}
span.E-potniSlog19
{mso-style-type:personal;
font-family:"Garamond",serif;
color:windowtext;}
span.E-potniSlog20
{mso-style-type:personal-compose;
font-family:"Garamond",serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:70.85pt 70.85pt 70.85pt 70.85pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=SL link="#0563C1" vlink="#954F72"><div class=WordSection1><p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;background:white'><span lang=EN-US><a href="https://bioendocar.eu/final-symposium-basic-information/"><span lang=SL style='font-size:12.0pt;font-family:"Times New Roman",serif;color:windowtext;mso-fareast-language:SL;text-decoration:none'><img border=0 width=610 height=232 style='width:6.3541in;height:2.4166in' id="Slika_x0020_1" src="cid:image002.png@01D8087C.8CF80120"></span></a></span><span style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-language:SL'><o:p></o:p></span></p><p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;background:white'><span style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-language:SL'><o:p> </o:p></span></p><p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;background:white'><span style='font-size:12.0pt;font-family:"Garamond",serif;mso-fareast-language:SL'>Spoštovani!<o:p></o:p></span></p><p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;background:white'><span style='font-size:12.0pt;font-family:"Garamond",serif;mso-fareast-language:SL'><o:p> </o:p></span></p><p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;background:white'><span style='font-size:12.0pt;font-family:"Garamond",serif;mso-fareast-language:SL'>Vabimo vas, da se udeležite <b>zaključnega srečanja projekta ERA-NET Transcan2 </b></span><b><span style='font-size:12.0pt;font-family:"Garamond",serif'><a href="https://bioendocar.eu"><span style='mso-fareast-language:SL'>BioEndoCar</span></a></span></b><span style='font-size:12.0pt;font-family:"Garamond",serif;mso-fareast-language:SL'>, ki ga koordinira UL MF. Dvodnevni dogodek bo potekal <b>24. in 25. marca 2022</b> v Portorožu ter preko spleta in je namenjen zdravnikom in raziskovalcem, ki jih zanimajo translacijske raziskave. Srečanje se bo osredotočilo na klinične izzive pri zdravljenju raka endometrija, nove možnosti diagnostike in napovedi prognoze, proteomske in metabolomske pristope za odkrivanje biooznačevalcev za personalizirano zdravljenje, pomen biobank in eksperimentalne modele: od celičnih linij, 3D kultur do organoidov. Srečanje bo zaključilo plenarno predavanje dr. Hanny Pijnenborgz, predsednice Evropske mreže za individualizirano zdravljenje raka endometrija (</span><b><span style='font-size:12.0pt;font-family:"Garamond",serif'><a href="https://www.esgo.org/network/enitec/"><span style='mso-fareast-language:SL'>ENITEC</span></a></span></b><span style='font-size:12.0pt;font-family:"Garamond",serif;mso-fareast-language:SL'>).<o:p></o:p></span></p><p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;background:white'><span style='font-size:12.0pt;font-family:"Garamond",serif;mso-fareast-language:SL'><o:p> </o:p></span></p><p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;background:white'><span style='font-size:12.0pt;font-family:"Garamond",serif;mso-fareast-language:SL'>Poleg predavanj vabljenih predavateljev z Nizozemske, Nemčije, Norveške, Poljske, Češke, Italije, Estonije in Slovenije bo srečanje vključevalo tudi kratka predavanja, ki jih bo Znanstveni odbor izbral na osnovi oddanih abstraktov. Vsi prispevki bodo objavljeni v knjigi abstraktov. <b>Udeležba na srečanju je brezplačna, potrebna pa je </b></span><b><span style='font-size:12.0pt;font-family:"Garamond",serif'><a href="https://bioendocar.eu/final-symposium-registration"><span style='mso-fareast-language:SL'>registracija</span></a></span></b><b><span style='font-size:12.0pt;font-family:"Garamond",serif;mso-fareast-language:SL'>.</span></b><span style='font-size:12.0pt;font-family:"Garamond",serif;mso-fareast-language:SL'> Rok za registracijo je 15. januar, rok za</span><span style='font-size:12.0pt;font-family:"Garamond",serif'><a href="https://bioendocar.eu/final-symposium-abstract-submission/"><span style='mso-fareast-language:SL;text-decoration:none'> </span><b><span style='mso-fareast-language:SL'>oddajo abstraktov</span></b></a></span><span style='font-size:12.0pt;font-family:"Garamond",serif;mso-fareast-language:SL'> je 15. februar 2022.<o:p></o:p></span></p><p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;background:white'><span style='font-size:12.0pt;font-family:"Garamond",serif;mso-fareast-language:SL'><o:p> </o:p></span></p><p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;background:white'><span style='font-size:12.0pt;font-family:"Garamond",serif'>Srečanje je v postopku pridobivanja akreditacije <span style='color:black'>ACCME® in <span style='background:white'>kreditnih točk Zdravniške zbornice Slovenije.</span></span></span><span style='font-size:12.0pt;font-family:"Garamond",serif;mso-fareast-language:SL'> Več informacij o srečanju najdete na </span><b><span style='font-size:12.0pt;font-family:"Garamond",serif'><a href="https://bioendocar.eu/final-symposium-basic-information/"><span style='mso-fareast-language:SL'>spletni strani srečanja</span></a></span></b><span style='font-size:12.0pt;font-family:"Garamond",serif;mso-fareast-language:SL'>.</span><span style='font-size:12.0pt;font-family:"Garamond",serif'><o:p></o:p></span></p><p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;background:white'><span style='font-size:12.0pt;font-family:"Garamond",serif;mso-fareast-language:SL'><o:p> </o:p></span></p><p class=MsoNormal style='text-align:justify'><span style='font-size:12.0pt;line-height:105%;font-family:"Garamond",serif'>Organizacijski odbor <o:p></o:p></span></p><p class=MsoNormal><span style='font-size:12.0pt;line-height:105%;font-family:"Garamond",serif'><o:p> </o:p></span></p></div></body></html>